Business Context and Reporting Period
This Form 8-K was filed by Platform Specialty Products Corporation on November 3, 2014. The filing serves as a voluntary disclosure of financial information related to the proposed acquisition of Arysta LifeScience Limited ("Arysta") for approximately $3.51 billion. The report incorporates by reference Arysta's audited financial statements for fiscal years 2012 and 2013, unaudited statements for the six months ended June 30, 2014, and Platform's unaudited pro forma combined financial statements.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached exhibits (Exhibits 99.1, 99.2, 99.3, and 99.4) which are incorporated by reference but not detailed in the body of this summary.
- Transaction Value: Approximately $3.51 billion for the Arysta Acquisition.
- Pro Forma Basis: Includes the proposed Arysta Acquisition, the proposed Chemtura AgroSolutions (CAS) Acquisition, and the completed MacDermid Holdings acquisition.
Material Changes
The primary material event is the progression of the Arysta Acquisition, previously disclosed on October 21, 2014. The filing updates investors with detailed financial data regarding the target company and the combined entity's projected financial position. No specific period-over-period financial changes are quantified in the text of this report.
Guidance, Outlook, and Risks
Outlook and Risks: The registrant explicitly states that there can be no assurance that the Arysta Acquisition will close, be completed in the anticipated timeframe, or be completed on the currently anticipated terms. The transaction remains subject to customary closing conditions.
Management Commentary: The filing focuses on providing transparency regarding the target's financial health and the pro forma impact of the transaction on Platform Specialty Products Corporation.
Investor Verification Checklist
- Review Exhibit 99.1 for Arysta's Management Discussion of Operations and Cash Flows.
- Examine Exhibit 99.2 and 99.3 for Arysta's audited and unaudited consolidated balance sheets and income statements.
- Analyze Exhibit 99.4 for Platform's pro forma financial statements, which model the impact of the Arysta, CAS, and MacDermid acquisitions.
- Verify the specific closing conditions and financing details associated with the $3.51 billion transaction.
- Confirm the status of the proposed Chemtura AgroSolutions (CAS) Acquisition referenced in the pro forma data.